Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase III Study to Evaluate Efficacy and Safety of ENERGI-F703 GEL in Subjects With Diabetic Foot Ulcers

NCT05930210 is registered in ClinicalTrials.gov with Energenesis Biomedical Co., Ltd. as lead sponsor.

NCT NCT05930210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05930210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase III Study to Evaluate Efficacy and Safety of ENERGI-F703 GEL in Subjects With Diabetic Foot Ulcers
Lead sponsor
Energenesis Biomedical Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
May 30, 2023
Completion date
March 31, 2026
Enrollment
230 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, diabetic foot ulcer, foot ulcer, wound